| 09/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +300,000(L) | HKD 3.021(L) | 872,288,000(L) | 29.53 | | 07/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +6,000,000(L) | HKD 3.006(L) | 871,988,000(L) | 29.52 | | 07/04/2025 | 曲繼廣 | 1113(L) | +6,000,000(L) | HKD 3.006(L) | 1,162,626,000(L) | 39.36 | | 03/04/2025 | 曲繼廣 | 1113(L) | +3,000,000(L) | HKD 3.355(L) | 1,156,626,000(L) | 39.15 | | 03/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +3,000,000(L) | HKD 3.355(L) | 865,988,000(L) | 29.31 | | 01/04/2025 | 曲繼廣 | 1113(L) | +3,000,000(L) | HKD 3.363(L) | 1,152,226,000(L) | 39.01 | | 01/04/2025 | 曲繼廣 | 1101(L) | +1,400,000(L) | HKD 3.374(L) | 1,153,626,000(L) | 39.05 | | 01/04/2025 | China Pharmaceutical Company Limited | 1710(L) | +3,000,000(L) | HKD 3.363(L) | 862,988,000(L) | 29.22 | | 31/03/2025 | China Pharmaceutical Company Limited | 1710(L) | +2,800,000(L) | HKD 3.191(L) | 859,988,000(L) | 29.11 | | 31/03/2025 | 曲繼廣 | 1113(L) | +2,800,000(L) | HKD 3.191(L) | 1,149,226,000(L) | 38.90 | | 21/02/2025 | UBS Group AG | 1201(L) | -372,000(L) | HKD 3.244(L) | 265,496,063(L) | 8.98 | | 20/02/2025 | UBS Group AG | 1101(L) | +198,000(L) | HKD 3.335(L) | 265,867,466(L) | 9.00 | | 18/02/2025 | UBS Group AG | 1201(L) | -448,204(L) | HKD 3.238(L) | 265,697,464(L) | 8.99 | | 08/01/2025 | 曲繼廣 | 1113(L) | +500,000(L) | HKD 3.263(L) | 1,146,426,000(L) | 38.76 | | 08/01/2025 | China Pharmaceutical Company Limited | 1710(L) | +500,000(L) | HKD 3.263(L) | 857,188,000(L) | 28.98 | | 07/01/2025 | China Pharmaceutical Company Limited | 1710(L) | +600,000(L) | HKD 3.337(L) | 856,688,000(L) | 28.96 | | 07/01/2025 | 曲繼廣 | 1113(L) | +600,000(L) | HKD 3.337(L) | 1,145,926,000(L) | 38.74 | | 06/01/2025 | China Pharmaceutical Company Limited | 1710(L) | +600,000(L) | HKD 3.388(L) | 856,088,000(L) | 28.94 | | 06/01/2025 | 曲繼廣 | 1113(L) | +600,000(L) | HKD 3.388(L) | 1,145,326,000(L) | 38.72 | | 03/01/2025 | 曲繼廣 | 1113(L) | +660,000(L) | HKD 3.372(L) | 1,144,726,000(L) | 38.70 | | 03/01/2025 | China Pharmaceutical Company Limited | 1710(L) | +660,000(L) | HKD 3.372(L) | 855,488,000(L) | 28.92 | | 26/11/2024 | 曲繼廣 | 1101(L) | +1,300,000(L) | HKD 3.490(L) | 1,144,066,000(L) | 38.68 | | 20/11/2024 | 曲繼廣 | 1101(L) | +400,000(L) | HKD 3.880(L) | 1,142,766,000(L) | 38.63 | | 19/11/2024 | 曲繼廣 | 1101(L) | +900,000(L) | HKD 3.772(L) | 1,142,366,000(L) | 38.62 | | 15/11/2024 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD 3.807(L) | 1,141,466,000(L) | 38.59 | | 15/11/2024 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD 3.807(L) | 854,828,000(L) | 28.90 | | 14/11/2024 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD 3.817(L) | 1,140,466,000(L) | 38.56 | | 14/11/2024 | China Pharmaceutical Company Limited | 1710(L) | +1,000,000(L) | HKD 3.817(L) | 853,828,000(L) | 28.87 | | 06/11/2024 | UBS Group AG | 1104(L) | +34,000(L) | | 295,795,721(L) | 10.00 | | 05/11/2024 | UBS Group AG | 1201(L) | -62,000(L) | HKD 3.820(L) | 295,775,721(L) | 9.99 | | 01/11/2024 | UBS Group AG | 1104(L) | +1,073,732(L) | | 296,837,530(L) | 10.04 | | 30/10/2024 | China Pharmaceutical Company Limited | 1710(L) | +780,000(L) | HKD 3.718(L) | 852,828,000(L) | 28.83 | | 30/10/2024 | 曲繼廣 | 1113(L) | +780,000(L) | HKD 3.718(L) | 1,139,466,000(L) | 38.52 | | 29/10/2024 | 曲繼廣 | 1113(L) | +1,280,000(L) | HKD 3.753(L) | 1,138,686,000(L) | 38.50 | | 29/10/2024 | China Pharmaceutical Company Limited | 1710(L) | +1,280,000(L) | HKD 3.753(L) | 852,048,000(L) | 28.81 | | 21/10/2024 | China Pharmaceutical Company Limited | 1710(L) | +800,000(L) | HKD 3.898(L) | 850,768,000(L) | 28.76 | | 21/10/2024 | 曲繼廣 | 1113(L) | +800,000(L) | HKD 3.898(L) | 1,137,406,000(L) | 38.45 | | 17/10/2024 | UBS Group AG | 1205(L) | -300,000(L) | | 295,665,644(L) | 9.99 | | 16/10/2024 | UBS Group AG | 1104(L) | +980,000(L) | | 296,385,646(L) | 10.02 | | 14/10/2024 | 曲繼廣 | 1113(L) | +1,000,000(L) | HKD 4.137(L) | 1,136,606,000(L) | 38.42 | | | 1 2 3 4 |
|